REG - Roquefort Theraptcs. - Results of AGM

Roquefort TherapeuticsAnnouncement

26/06/2025 13:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250626:nRSZ6026Oa&default-theme=true

RNS Number : 6026O  Roquefort Therapeutics PLC  26 June 2025

26 June 2025

Roquefort Therapeutics plc

("Roquefort Therapeutics" or the "Company")

 

Results of AGM

 

Roquefort Therapeutics (LSE:ROQ), the Main Market listed biotech company
focused on developing first in class medicines in the high value and high
growth immunology and oncology markets, is pleased to announce that at the
Company's Annual General Meeting ("AGM") held earlier today, all resolutions
proposed were duly passed.

 

The resolutions were put to shareholders via a poll, the results of which were
as follows:

 Resolution      Poll Results                              Total Votes Withheld*
         For     Against     Total Votes Cast
 1       Shares  15,989,492  205,120           16,194,612  289,738
         %       98.73%      1.27%
 2       Shares  15,758,683  432,163           16,190,846  293,504
         %       97.33%      2.67%
 3       Shares  15,668,163  522,683           16,190,846  293,504
         %       96.77%      3.23%
 4       Shares  15,842,448  352,163           16,194,611  289,739
         %       97.83%      2.17%
 5       Shares  15,842,449  352,163           16,194,612  289,738
         %       97.83%      2.17%
 6       Shares  15,989,492  205,120           16,194,612  289,738
         %       98.73%      1.27%
 7       Shares  15,989,492  205,120           16,194,612  289,738
         %       98.73%      1.27%
 8       Shares  15,671,929  522,683           16,194,612  289,738
         %       96.77%      3.23%
 9       Shares  15,636,863  557,749           16,194,612  289,738
         %       96.56%      3.44%

* Votes withheld are not counted in the calculation of the proportion of votes
for and against a resolution.

 

The total number of ordinary shares in issue on 24 June 2025, the deadline for
casting votes by proxy in advance of the AGM, was 157,444,030 shares.  10.3%
of voting capital was instructed in respect of the resolutions put to the AGM.

 
Enquiries:
 Roquefort Therapeutics plc                               +44 (0)20 3918 8633
 Stephen West (Chairman) / Dr Darrin Disley (Interim MD)
 SP Angel Corporate Finance LLP (Broker)                  +44 (0) 20 3470 0470

 David Hignell / Vadim Alexandre / Devik Mehta
 Burson Buchanan (Public Relations)                       +44 (0)20 7466 5000

 Ben Romney / Jamie Hooper
 Peak IR (Investor Relations)                             +33 (0)7 44 44 15 42

 Seb Wykeham

 

LEI: ‎254900P4SISIWOR9RH34

 

About Roquefort Therapeutics

Roquefort Therapeutics (LSE:ROQ) is developing first in class drugs in the
immunology and oncology markets prior to securing a value accretive exit.

 

Roquefort Therapeutics' portfolio consists of five novel patent-protected
pre-clinical anti-cancer and immunology assets.

 

For further information on Roquefort Therapeutics,
please visit www.roquefortplc.com (http://www.roquefortplc.com/)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGFLFSLREIRFIE